Division of Pharmacology, Faculty of Science, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, Netherlands.
Global Centre of Excellence Immunology, Danone Nutricia Research B.V., Utrecht, Netherlands.
Front Immunol. 2020 May 7;11:801. doi: 10.3389/fimmu.2020.00801. eCollection 2020.
The prevalence and incidence of allergic diseases is rising and these diseases have become the most common chronic diseases during childhood in Westernized countries. Early life forms a critical window predisposing for health or disease. Therefore, this can also be a window of opportunity for allergy prevention. Postnatally the gut needs to mature, and the microbiome is built which further drives the training of infant's immune system. Immunomodulatory components in breastmilk protect the infant in this crucial period by; providing nutrients that contain substrates for the microbiome, supporting intestinal barrier function, protecting against pathogenic infections, enhancing immune development and facilitating immune tolerance. The presence of a diverse human milk oligosaccharide (HMOS) mixture, containing several types of functional groups, points to engagement in several mechanisms related to immune and microbiome maturation in the infant's gastrointestinal tract. In recent years, several pathways impacted by HMOS have been elucidated, including their capacity to; fortify the microbiome composition, enhance production of short chain fatty acids, bind directly to pathogens and interact directly with the intestinal epithelium and immune cells. The exact mechanisms underlying the immune protective effects have not been fully elucidated yet. We hypothesize that HMOS may be involved in and can be utilized to provide protection from developing allergic diseases at a young age. In this review, we highlight several pathways involved in the immunomodulatory effects of HMOS and the potential role in prevention of allergic diseases. Recent studies have proposed possible mechanisms through which HMOS may contribute, either directly or indirectly, via microbiome modification, to induce oral tolerance. Future research should focus on the identification of specific pathways by which individual HMOS structures exert protective actions and thereby contribute to the capacity of the authentic HMOS mixture in early life allergy prevention.
过敏疾病的患病率和发病率正在上升,这些疾病已成为西化国家儿童期最常见的慢性疾病。生命早期形成了易患健康或疾病的关键窗口。因此,这也可能是预防过敏的机会之窗。出生后,肠道需要成熟,微生物组得以建立,这进一步推动了婴儿免疫系统的训练。母乳中的免疫调节成分通过以下方式在这个关键时期保护婴儿:提供含有微生物组基质的营养物质,支持肠道屏障功能,防止病原感染,增强免疫发育并促进免疫耐受。存在多样化的人乳寡糖(HMO)混合物,含有几种类型的功能基团,表明其参与了与婴儿胃肠道中免疫和微生物组成熟相关的几种机制。近年来,已经阐明了几种受 HMO 影响的途径,包括其增强微生物组组成、增加短链脂肪酸产生、直接与病原体结合以及直接与肠上皮细胞和免疫细胞相互作用的能力。HMO 产生免疫保护作用的确切机制尚未完全阐明。我们假设 HMO 可能参与并可用于提供保护,以防止年轻时发生过敏疾病。在这篇综述中,我们强调了 HMO 参与免疫调节作用的几种途径及其在预防过敏疾病中的潜在作用。最近的研究提出了 HMO 可能通过微生物组修饰直接或间接发挥作用的可能机制,从而诱导口服耐受。未来的研究应集中于确定 HMO 结构通过特定途径发挥保护作用的机制,从而为早期生命过敏预防中真实 HMO 混合物的能力做出贡献。